FDA Approves Secukinumab for Hidradenitis Suppurativa
Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.
Smitht Alexa Kimball Alexa Kimball Jennifer Hsiao Kunzmannk Jennifer Hsiao Kunzmannk Matthew Zirwas Novartis Cosentyx
Source: hcplive.com